Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 38985 | 4.52 |
09:34 ET | 4040 | 4.52 |
09:36 ET | 17196 | 4.44 |
09:38 ET | 2541 | 4.45 |
09:39 ET | 400 | 4.45 |
09:41 ET | 1348 | 4.5 |
09:43 ET | 300 | 4.5 |
09:45 ET | 430 | 4.52 |
09:48 ET | 1020 | 4.53 |
09:50 ET | 300 | 4.53 |
09:52 ET | 11227 | 4.565 |
09:54 ET | 4064 | 4.54 |
09:56 ET | 480 | 4.54 |
09:57 ET | 1000 | 4.5401 |
09:59 ET | 3144 | 4.55 |
10:01 ET | 2222 | 4.565 |
10:03 ET | 11937 | 4.565 |
10:06 ET | 471 | 4.565 |
10:08 ET | 8093 | 4.58 |
10:10 ET | 2686 | 4.575 |
10:12 ET | 1930 | 4.56 |
10:14 ET | 100 | 4.555 |
10:15 ET | 300 | 4.555 |
10:19 ET | 100 | 4.555 |
10:21 ET | 7258 | 4.59 |
10:24 ET | 200 | 4.595 |
10:26 ET | 3710 | 4.615 |
10:28 ET | 4367 | 4.625 |
10:30 ET | 7732 | 4.615 |
10:32 ET | 13694 | 4.575 |
10:33 ET | 1500 | 4.575 |
10:35 ET | 1440 | 4.575 |
10:37 ET | 6590 | 4.5725 |
10:39 ET | 9384 | 4.545 |
10:42 ET | 5109 | 4.5217 |
10:44 ET | 2415 | 4.525 |
10:46 ET | 650 | 4.525 |
10:48 ET | 400 | 4.53 |
10:50 ET | 1257 | 4.515 |
10:51 ET | 3775 | 4.49 |
10:53 ET | 900 | 4.49 |
10:55 ET | 8811 | 4.5 |
10:57 ET | 2168 | 4.49 |
11:00 ET | 4126 | 4.54 |
11:02 ET | 2128 | 4.53 |
11:04 ET | 600 | 4.525 |
11:06 ET | 2000 | 4.525 |
11:08 ET | 3480 | 4.515 |
11:09 ET | 700 | 4.51 |
11:11 ET | 4100 | 4.515 |
11:13 ET | 8641 | 4.505 |
11:15 ET | 2870 | 4.535 |
11:18 ET | 300 | 4.535 |
11:20 ET | 417 | 4.535 |
11:22 ET | 600 | 4.535 |
11:24 ET | 1202 | 4.535 |
11:26 ET | 1050 | 4.535 |
11:27 ET | 3919 | 4.535 |
11:29 ET | 100 | 4.535 |
11:31 ET | 1466 | 4.555 |
11:33 ET | 600 | 4.555 |
11:36 ET | 2674 | 4.555 |
11:38 ET | 1150 | 4.558 |
11:40 ET | 3457 | 4.55 |
11:42 ET | 4784 | 4.525 |
11:44 ET | 2000 | 4.515 |
11:45 ET | 600 | 4.515 |
11:47 ET | 14660 | 4.525 |
11:49 ET | 280 | 4.525 |
11:51 ET | 200 | 4.525 |
11:54 ET | 2963 | 4.535 |
11:56 ET | 300 | 4.53 |
11:58 ET | 617 | 4.53 |
12:00 ET | 650 | 4.5357 |
12:02 ET | 2652 | 4.545 |
12:03 ET | 500 | 4.545 |
12:05 ET | 1631 | 4.545 |
12:07 ET | 9319 | 4.525 |
12:09 ET | 1528 | 4.53 |
12:12 ET | 3811 | 4.52 |
12:14 ET | 8858 | 4.505 |
12:16 ET | 232 | 4.505 |
12:18 ET | 300 | 4.5 |
12:20 ET | 1400 | 4.505 |
12:21 ET | 4688 | 4.48 |
12:23 ET | 500 | 4.485 |
12:25 ET | 4031 | 4.495 |
12:27 ET | 2865 | 4.485 |
12:30 ET | 400 | 4.485 |
12:34 ET | 2421 | 4.485 |
12:36 ET | 7532 | 4.485 |
12:38 ET | 550 | 4.4884 |
12:39 ET | 200 | 4.48 |
12:41 ET | 100 | 4.48 |
12:43 ET | 44480 | 4.46 |
12:45 ET | 1100 | 4.465 |
12:48 ET | 200 | 4.46 |
12:50 ET | 9838 | 4.455 |
12:52 ET | 3875 | 4.46 |
12:54 ET | 1729 | 4.455 |
12:56 ET | 300 | 4.45 |
12:57 ET | 1200 | 4.45 |
12:59 ET | 100 | 4.455 |
01:01 ET | 3905 | 4.435 |
01:03 ET | 5579 | 4.45 |
01:06 ET | 2704 | 4.455 |
01:08 ET | 4594 | 4.44 |
01:10 ET | 2050 | 4.44 |
01:12 ET | 2126 | 4.455 |
01:15 ET | 1740 | 4.45 |
01:17 ET | 700 | 4.455 |
01:19 ET | 625 | 4.45 |
01:24 ET | 1533 | 4.4499 |
01:26 ET | 200 | 4.45 |
01:28 ET | 3021 | 4.46 |
01:30 ET | 417 | 4.475 |
01:32 ET | 300 | 4.475 |
01:33 ET | 1594 | 4.47 |
01:37 ET | 100 | 4.47 |
01:39 ET | 1967 | 4.485 |
01:42 ET | 831 | 4.485 |
01:44 ET | 8229 | 4.495 |
01:46 ET | 1200 | 4.495 |
01:50 ET | 3309 | 4.49 |
01:51 ET | 100 | 4.49 |
01:53 ET | 200 | 4.49 |
01:55 ET | 700 | 4.48 |
02:00 ET | 2300 | 4.48 |
02:02 ET | 200 | 4.48 |
02:04 ET | 8731 | 4.47 |
02:06 ET | 200 | 4.47 |
02:08 ET | 2077 | 4.475 |
02:09 ET | 100 | 4.47 |
02:11 ET | 300 | 4.4711 |
02:13 ET | 2350 | 4.46 |
02:15 ET | 100 | 4.46 |
02:18 ET | 2703 | 4.465 |
02:20 ET | 100 | 4.46 |
02:24 ET | 5325 | 4.455 |
02:26 ET | 100 | 4.46 |
02:27 ET | 4731 | 4.46 |
02:29 ET | 100 | 4.465 |
02:31 ET | 1789 | 4.46 |
02:33 ET | 4684 | 4.46 |
02:36 ET | 2388 | 4.47 |
02:38 ET | 100 | 4.465 |
02:40 ET | 459 | 4.46 |
02:42 ET | 100 | 4.46 |
02:44 ET | 1626 | 4.46 |
02:45 ET | 226 | 4.45 |
02:47 ET | 300 | 4.45 |
02:49 ET | 220 | 4.45 |
02:51 ET | 200 | 4.45 |
02:54 ET | 400 | 4.45 |
02:56 ET | 5280 | 4.47 |
02:58 ET | 1366 | 4.4795 |
03:00 ET | 126 | 4.475 |
03:02 ET | 100 | 4.48 |
03:03 ET | 2990 | 4.455 |
03:05 ET | 835 | 4.4599 |
03:09 ET | 1025 | 4.455 |
03:12 ET | 3769 | 4.465 |
03:14 ET | 426 | 4.46 |
03:16 ET | 1500 | 4.465 |
03:18 ET | 503 | 4.46 |
03:20 ET | 3646 | 4.45 |
03:21 ET | 300 | 4.455 |
03:23 ET | 1600 | 4.455 |
03:25 ET | 1150 | 4.455 |
03:27 ET | 2381 | 4.47 |
03:30 ET | 300 | 4.465 |
03:32 ET | 1265 | 4.465 |
03:34 ET | 9032 | 4.48 |
03:36 ET | 5898 | 4.485 |
03:38 ET | 16327 | 4.505 |
03:39 ET | 1200 | 4.5098 |
03:41 ET | 19081 | 4.5 |
03:43 ET | 5044 | 4.5 |
03:45 ET | 1869 | 4.5 |
03:48 ET | 18955 | 4.49 |
03:50 ET | 20784 | 4.475 |
03:52 ET | 16950 | 4.465 |
03:54 ET | 23783 | 4.455 |
03:56 ET | 6660 | 4.47 |
03:57 ET | 19730 | 4.46 |
03:59 ET | 44430 | 4.44 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 3.1B | -26.8x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Xenon Pharmaceuticals Inc | 3.0B | -14.7x | --- |
Apogee Therapeutics Inc | 2.9B | -24.6x | --- |
Biohaven Ltd | 3.3B | -5.5x | --- |
IDEAYA Biosciences Inc | 3.1B | -20.2x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.1B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.26 |
EPS | $-0.17 |
Book Value | $0.11 |
P/E Ratio | -26.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.